About the Company
We do not have any company description for Caribou Biosciences, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Caribou Biosciences, Inc.
Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an ... - Nasdaq
Caribou Biosciences, Inc. CRBU shares ended the last trading session 45.6% higher at $5.94. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst ...
Hedge funds don't have many shares in Caribou Biosciences. Looking at our data, we can see that the largest shareholder is BlackRock, Inc. with 7.2% of shares outstanding.
Caribou Biosciences, Inc. Shareholders are Encouraged to Contact ...
What Now: You may be eligible to participate in the class action against Caribou Biosciences, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to ...
Caribou Biosciences, Inc. Announces Strategic Pipeline ... - Nasdaq
Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...
Caribou Biosciences, Inc. Class Action: Levi & Korsinsky Reminds ...
Provided by PR NewswireFeb 11, 2025 10:45am Caribou Biosciences, Inc. Class Action: Levi & Korsinsky Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead ...
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current ...
Caribou Biosciences Reports First Quarter 2023 Financial Results and ...
BERKELEY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for ...
Caribou Biosciences, Inc. Sued for Securities Law Violations ...
THE LAWSUIT: A class action securities lawsuit was filed against Caribou Biosciences, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...
Caribou Biosciences Announces Closing of Upsized Initial Public ...
Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of it ...
Similar Companies
Loading the latest forecasts...